Circ-CIMIRC inhibition alleviates CIH-induced myocardial damage via FbxL4-mediated ubiquitination of PINK1
- PMID: 38333696
- PMCID: PMC10850785
- DOI: 10.1016/j.isci.2024.108982
Circ-CIMIRC inhibition alleviates CIH-induced myocardial damage via FbxL4-mediated ubiquitination of PINK1
Abstract
Obstructive sleep apnea (OSA) is a common sleep disordered breathing diseases that characterized by chronic intermittent hypoxia (CIH). This work aimed to explore the role of circ-CIMIRC in CIH-induced myocardial injury. CIH aggravated myocardial tissue damage in rats. Circ_CIMIRC overexpression promoted apoptosis and reduced the colocalization of Tom20 and Parkin and mitophagy in CIH-treated H9c2 cells. Additionally, FbxL4 interacted with PINK1, FbxL4 silencing reduced PINK1 ubiquitination in H9c2 cells. Two major ubiquitination sites (K319 and K433) were responsible for ubiquitination of PINK1. Circ_CIMIRC promoted FbxL4-mediated ubiquitination and degradation of PINK1. Furthermore, circ_CIMIRC inhibition alleviated the pathological damage, fibrosis and apoptosis of myocardial tissues, reduced oxidative stress in CIH rats. In conclusion, circ_CIMIRC silencing repressed FbxL4-mediated ubiquitination and degradation of PINK1 and then enhanced PINK1/Parkin-mediated mitophagy, thereby alleviating myocardial damage in CIH rats. Thus, circ_CIMIRC may be a potential strategy to alleviate CIH-induced myocardial damage.
Keywords: Cell biology; Molecular biology.
© 2024 The Authors.
Conflict of interest statement
The authors declare no competing interests.
Figures
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/fx1.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/gr1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/gr2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/gr3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/gr4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/gr5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/gr6.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/gr7.gif)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10850785/bin/gr8.gif)
Similar articles
-
Chronic intermittent hypoxia-induced BNIP3 expression mitigates contractile dysfunction and myocardial injury in animal and cell model via modulating autophagy.Hum Cell. 2023 Mar;36(2):631-642. doi: 10.1007/s13577-022-00851-w. Epub 2023 Jan 10. Hum Cell. 2023. PMID: 36627546
-
Banxia-Houpu decoction diminishes iron toxicity damage in heart induced by chronic intermittent hypoxia.Pharm Biol. 2022 Dec;60(1):609-620. doi: 10.1080/13880209.2022.2043392. Pharm Biol. 2022. PMID: 35286247 Free PMC article.
-
Astragaloside IV attenuates chronic intermittent hypoxia-induced myocardial injury by modulating Ca2+ homeostasis.Cell Biochem Funct. 2020 Aug;38(6):710-720. doi: 10.1002/cbf.3538. Epub 2020 Apr 19. Cell Biochem Funct. 2020. PMID: 32306464
-
DL-Propargylglycine protects against myocardial injury induced by chronic intermittent hypoxia through inhibition of endoplasmic reticulum stress.Sleep Breath. 2018 Sep;22(3):853-863. doi: 10.1007/s11325-018-1656-0. Epub 2018 May 16. Sleep Breath. 2018. PMID: 29770919
-
Obstructive sleep apnea and chronic intermittent hypoxia: a review.Chin J Physiol. 2006 Oct 31;49(5):234-43. Chin J Physiol. 2006. PMID: 17294831 Review.
References
-
- De Backer W. Obstructive sleep apnea/hypopnea syndrome. Panminerva Med. 2013;55:191–195. - PubMed
-
- Channaveerappa D., Lux J.C., Wormwood K.L., Heintz T.A., McLerie M., Treat J.A., King H., Alnasser D., Goodrow R.J., Ballard G., et al. Atrial electrophysiological and molecular remodelling induced by obstructive sleep apnoea. J. Cell Mol. Med. 2017;21:2223–2235. doi: 10.1111/jcmm.13145. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources